PMID- 36991096
OWN - NLM
STAT- MEDLINE
DCOM- 20230403
LR  - 20230419
IS  - 2045-2322 (Electronic)
IS  - 2045-2322 (Linking)
VI  - 13
IP  - 1
DP  - 2023 Mar 29
TI  - Efficacy of elotuzumab for multiple myeloma in reference to lymphocyte counts and 
      kappa/lambda ratio or B2 microglobulin.
PG  - 5159
LID - 10.1038/s41598-023-32426-6 [doi]
LID - 5159
AB  - Novel therapeutic drugs have dramatically improved the overall survival of 
      patients with multiple myeloma. We sought to identify the characteristics of 
      patients likely to exhibit a durable response to one such drug, elotuzumab, by 
      analyzing a real-world database in Japan. We analyzed 179 patients who underwent 
      201 elotuzumab treatments. The median time to next treatment (TTNT) with the 95% 
      confidence interval was 6.29 months (5.18-9.20) in this cohort. Univariate 
      analysis showed that patients with any of the following had longer TTNT: no high 
      risk cytogenic abnormalities, more white blood cells, more lymphocytes, 
      non-deviated kappa/lambda ratio, lower beta(2) microglobulin levels (B2MG), fewer prior drug 
      regimens, no prior daratumumab use and better response after elotuzumab 
      treatment. A multivariate analysis showed that TTNT was longer in patients with 
      more lymphocytes (>/= 1400/muL), non-deviated kappa/lambda ratio (0.1-10), lower B2MG 
      (< 5.5 mg/L) and no prior daratumumab use. We proposed a simple scoring system to 
      predict the durability of the elotuzumab treatment effect by classifying the 
      patients into three categories based on their lymphocyte counts (0 points 
      for >/= 1400/muL and 1 point for < 1400/muL) and kappa/lambda ratio (0 points for 0.1-10 and 1 
      point for < 0.1 or >/= 10) or B2MG (0 points for < 5.5 mg/L and 1 point 
      for >/= 5.5 mg/L). The patients with a score of 0 showed significantly longer TTNT 
      (p < 0.001) and better survival (p < 0.001) compared to those with a score of 1 
      or 2. Prospective cohort studies of elotuzumab treatment may be needed to 
      validate the usefulness of our new scoring system.
CI  - (c) 2023. The Author(s).
FAU - Shimazu, Yutaka
AU  - Shimazu Y
AD  - Department of Hematology and Oncology Graduate School of Medicine, Kyoto 
      University, 54, Kawaramachi, Shogoin, Sakyoku, Kyoto, 606-8507, Japan.
FAU - Kanda, Junya
AU  - Kanda J
AD  - Department of Hematology and Oncology Graduate School of Medicine, Kyoto 
      University, 54, Kawaramachi, Shogoin, Sakyoku, Kyoto, 606-8507, Japan. 
      jkanda16@kuhp.kyoto-u.ac.jp.
FAU - Kosugi, Satoru
AU  - Kosugi S
AD  - Department of Internal Medicine (Hematology), Toyonaka Municipal Hospital, 
      Toyonaka, Japan.
FAU - Ito, Tomoki
AU  - Ito T
AD  - First Department of Internal Medicine, Kansai Medical University, Hirakata, 
      Japan.
FAU - Kaneko, Hitomi
AU  - Kaneko H
AD  - Department of Hematology, Japanese Red Cross Osaka Hospital, Osaka, Japan.
FAU - Imada, Kazunori
AU  - Imada K
AD  - Department of Hematology, Japanese Red Cross Osaka Hospital, Osaka, Japan.
FAU - Shimura, Yuji
AU  - Shimura Y
AD  - Division of Hematology and Oncology, Department of Medicine, Kyoto Prefectural 
      University of Medicine, Kyoto, Japan.
FAU - Fuchida, Shin-Ichi
AU  - Fuchida SI
AD  - Department of Hematology, Japan Community Health Care Organization Kyoto 
      Kuramaguchi Medical Center, Kyoto, Japan.
FAU - Fukushima, Kentaro
AU  - Fukushima K
AD  - Department of Hematology and Oncology, Osaka University Graduate School of 
      Medicine, Suita, Japan.
FAU - Tanaka, Hirokazu
AU  - Tanaka H
AD  - Department of Hematology and Rheumatology, Kindai University Faculty of Medicine, 
      Higashiosaka, Japan.
FAU - Yoshihara, Satoshi
AU  - Yoshihara S
AD  - Division of Hematology, Department of Internal Medicine, Hyogo College of 
      Medicine, Nishinomiya, Japan.
FAU - Ohta, Kensuke
AU  - Ohta K
AD  - Hematology Ohta Clinic, Shinsaibashi, Japan.
FAU - Uoshima, Nobuhiko
AU  - Uoshima N
AD  - Department of Hematology, Japanese Red Cross Kyoto Daini Hospital, Kyoto, Japan.
FAU - Yagi, Hideo
AU  - Yagi H
AD  - Department of Hematology and Oncology, Nara Prefecture General Medical Center, 
      Nara, Japan.
FAU - Shibayama, Hirohiko
AU  - Shibayama H
AD  - Department of Hematology, National Hospital Organization Osaka National Hospital, 
      Osaka, Japan.
FAU - Yamamura, Ryosuke
AU  - Yamamura R
AD  - Department of Hematology, Osaka Saiseikai Nakatsu Hospital, Osaka, Japan.
FAU - Tanaka, Yasuhiro
AU  - Tanaka Y
AD  - Department of Hematology, Japanese Red Cross Wakayama Medical Center, Wakayama, 
      Japan.
FAU - Uchiyama, Hitoji
AU  - Uchiyama H
AD  - Department of Hematology, Japanese Red Cross Kyoto Daiichi Hospital, Kyoto, 
      Japan.
FAU - Onda, Yoshiyuki
AU  - Onda Y
AD  - Department of Hematology, Japanese Red Cross Takatsuki Hospital, Takatsuki, 
      Japan.
FAU - Adachi, Yoko
AU  - Adachi Y
AD  - Department of Internal Medicine, Japan Community Health Care Organization Kobe 
      Central Hospital, Kobe, Japan.
FAU - Hanamoto, Hitoshi
AU  - Hanamoto H
AD  - Department of Hematology, Kindai University Nara Hospital, Ikoma, Japan.
FAU - Takahashi, Ryoichi
AU  - Takahashi R
AD  - Department of Hematology, Omihachiman Community Medical Center, Omihachiman, 
      Japan.
FAU - Matsuda, Mitsuhiro
AU  - Matsuda M
AD  - Department of Hematology, PL General Hospital, Tondabayashi, Japan.
FAU - Miyoshi, Takashi
AU  - Miyoshi T
AD  - Department of Hematology, Uji Tokushukai Hospital, Uji, Japan.
FAU - Takakuwa, Teruhito
AU  - Takakuwa T
AD  - Department of Hematology, Osaka Metropolitan University Graduate School of 
      Medicine, Osaka, Japan.
FAU - Hino, Masayuki
AU  - Hino M
AD  - Department of Hematology, Osaka Metropolitan University Graduate School of 
      Medicine, Osaka, Japan.
FAU - Hosen, Naoki
AU  - Hosen N
AD  - Department of Hematology and Oncology, Osaka University Graduate School of 
      Medicine, Suita, Japan.
FAU - Nomura, Shosaku
AU  - Nomura S
AD  - First Department of Internal Medicine, Kansai Medical University, Hirakata, 
      Japan.
FAU - Shimazaki, Chihiro
AU  - Shimazaki C
AD  - Department of Hematology, Japan Community Health Care Organization Kyoto 
      Kuramaguchi Medical Center, Kyoto, Japan.
FAU - Matsumura, Itaru
AU  - Matsumura I
AD  - Department of Hematology and Rheumatology, Kindai University Faculty of Medicine, 
      Higashiosaka, Japan.
FAU - Takaori-Kondo, Akifumi
AU  - Takaori-Kondo A
AD  - Department of Hematology and Oncology Graduate School of Medicine, Kyoto 
      University, 54, Kawaramachi, Shogoin, Sakyoku, Kyoto, 606-8507, Japan.
FAU - Kuroda, Junya
AU  - Kuroda J
AD  - Division of Hematology and Oncology, Department of Medicine, Kyoto Prefectural 
      University of Medicine, Kyoto, Japan.
LA  - eng
PT  - Journal Article
DEP - 20230329
PL  - England
TA  - Sci Rep
JT  - Scientific reports
JID - 101563288
RN  - 1351PE5UGS (elotuzumab)
RN  - 0 (beta 2-Microglobulin)
SB  - IM
MH  - Humans
MH  - Antineoplastic Combined Chemotherapy Protocols/therapeutic use
MH  - Lymphocyte Count
MH  - *Multiple Myeloma
MH  - Prospective Studies
MH  - beta 2-Microglobulin/metabolism
PMC - PMC10060246
COIS- J. Kanda received honorarium from Bristol-Myers Squibb Co., Janssen 
      Pharmaceutical K.K., Takeda Pharmaceutical Co., Ltd., Sanofi K.K. and Ono 
      Pharmaceutical Co., Ltd., and is an advisory role in Janssen Pharmaceutical K.K, 
      and Novartis Pharma K.K. T.I. honorarium from Bristol-Myers Squibb Co., Takeda 
      Pharmaceutical Co., Ltd. and Sanofi K.K.; and research funding from Bristol-Myers 
      Squibb Co. K.I. received honorarium from Bristol-Myers Squibb Co., Janssen 
      Pharmaceutical K.K., Takeda Pharmaceutical Co., Ltd., Ono Pharmaceutical Co., 
      Ltd., Novartis Pharma K.K., Kyowa Kirin Co., Ltd., Celgene K.K., Nippon Shinyaku 
      Co., Ltd., Chugai Pharmaceutical Co., Ltd., Otsuka Pharmaceutical Co. Ltd., 
      Astellas Pharma Inc., Sumitomo Dainippon Pharma Co., Ltd. and Meiji Seika Pharma 
      Co. Ltd. S.F. received honorarium from Takeda Pharmaceutical Co., Ltd., Janssen 
      Pharmaceutical K.K., Sanofi K.K., Ono Pharmaceutical Co., Ltd., and Bristol-Myers 
      Squibb Co. H.T. received personal fees from Bristol-Myers Squibb Co. (Celgene 
      K.K.), personal fees from Novartis Pharma K.K., grants from Kyowa Kirin Co., Ltd. 
      H.S. reports honoraria from Takeda Pharmaceutical Co., Ltd., Ono Pharmaceutical 
      Co., Ltd., Novartis Pharma K.K., Celgene K.K., Janssen Pharmaceutical K.K., 
      Chugai Pharmaceutical Co., Ltd., Sanofi K.K., AstraZeneca K.K., AbbVie G.K., 
      SymBio Pharmaceuticals Ltd., Eisai Co., Ltd., and Kyowa Kirin Co., Ltd.; and 
      research funding from Pharma Essentia Japan K.K., Janssen Pharmaceutical K.K., 
      Ono Pharmaceutical Co., Ltd., Celgene K.K., Novartis Pharma K.K., Sanofi K.K., 
      AstraZeneca K.K., AbbVie G.K., Eisai Co., Ltd., HUYA Bioscience International, 
      LLC., and Chugai Pharmaceutical Co., Ltd.; and scholarship endowment from 
      Astellas Pharma Inc., Teijin Pharma Ltd., Shionogi & Co., Ltd., Eisai Co., Ltd., 
      Sanofi K.K., Taiho Pharmaceutical Co., Ltd., and Nippon Shinyaku Co., Ltd. I.M. 
      received personal fees from Bristol-Myers Squibb Co. (Celgene K.K.), personal 
      fees from Novartis Pharma K.K., grants and personal fees from Otsuka 
      Pharmaceutical Co., Ltd., personal fees from Pfizer Japan Inc., during the 
      conduct of the study; grants from Ono Pharmaceutical Co., Ltd., personal fees 
      from Janssen Pharmaceutical K.K, grants from Nippon Shinyaku Co., Ltd., grants 
      from Kyowa Kirin Co., Ltd., grants from Sumitomo Dainippon Pharma Co., Ltd., 
      grants from Shionogi & Co., Ltd., grants from Teijin Pharma limited., grants from 
      Boehringer Ingelheim Co., Ltd., grants from Sanofi K.K., grants from Chugai 
      Pharmaceutical Co., Ltd., grants from Eisai Co., Ltd., grants from MSD K.K, 
      grants from Asahi Kasei Pharma Corporation, grants and personal fees from 
      Astellas Pharma Inc., grants and personal fees from Takeda Pharmaceutical Co., 
      Ltd., grants from Japan Blood Products Organization, grants from Nihon 
      Pharmaceutical Co., Ltd., grants and personal fees from Daiichi Sankyo Co., Ltd., 
      grants and personal fees from AbbVie GK, grants from Taiho Pharmaceutical Co., 
      Ltd., grants from Mitsubishi Tanabe Pharma Corporation, grants from Nippon Kayaku 
      Co., Ltd., grants from CSL Behring LLC, grants from Mundipharma K.K, grants from 
      Ayumi Pharmaceutical Corporation, grants from Eli Lilly Japan K.K., grants from 
      Actelion Pharmaceuticals Japan Ltd., personal fees from Amgen BioPharma K.K., 
      outside the submitted work. C.S. received honoraria from Janssen Pharmaceutical 
      K.K., Sanofi K.K., and Bristol-Myers Squibb. Co. A. Takaori-Kondo serves as an 
      advisor for Megakaryon and receives research fundings from Ono Pharmaceutical 
      Co., Ltd., DSK, and Cognano. J. Kuroda. received research funding from Kyowa 
      Kirin Co., Ltd., Chugai Pharmaceutical Co., Ltd., Ono Pharmaceutical Co., Ltd., 
      Sanofi K.K., Eisai, Bristol-Myers Squibb Co., Sysmex, Dainippon Sumitomo Pharma 
      Co., Ltd., Nippon Shinyaku Co., Ltd., AbbVie GK, Teijin Pharma Ltd. and Otsuka 
      Pharmaceutical Co., Ltd., has received honoraria from Janssen Pharmaceutical K.K, 
      Kyowa Kirin Co., Ltd., Chugai Pharmaceutical Co., Ltd., Ono Pharmaceutical Co., 
      Ltd., Sanofi K.K., Eisai Co., Ltd., SymBio Pharmaceuticals Ltd., Bristol-Myers 
      Squibb Co, Astellas Pharma Inc., Pfizer Japan Inc., Nippon Shinyaku Co., Ltd., 
      Daiichi Sankyo Co., Ltd., Dainippon Sumitomo Pharma Co., Ltd., AbbVie GK and 
      Otsuka Pharmaceutical Co., Ltd., and is a consultant for Janssen Pharmaceutical 
      K.K, and Bristol-Myers Squibb Co. The other authors have no conflict of interest.
EDAT- 2023/03/30 06:00
MHDA- 2023/03/31 06:42
PMCR- 2023/03/29
CRDT- 2023/03/29 23:19
PHST- 2022/12/13 00:00 [received]
PHST- 2023/03/27 00:00 [accepted]
PHST- 2023/03/31 06:42 [medline]
PHST- 2023/03/29 23:19 [entrez]
PHST- 2023/03/30 06:00 [pubmed]
PHST- 2023/03/29 00:00 [pmc-release]
AID - 10.1038/s41598-023-32426-6 [pii]
AID - 32426 [pii]
AID - 10.1038/s41598-023-32426-6 [doi]
PST - epublish
SO  - Sci Rep. 2023 Mar 29;13(1):5159. doi: 10.1038/s41598-023-32426-6.